ITCC-104: HEM-iSMART International Proof of Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory HEMatological Malignancies in Children, Sub-Protocol E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

HEM-iSMART is a master protocol which investigates multiple investigational medicinal products in children, adolescents and young adults (AYA) with relapsed/refractory (R/R) ALL and LBL. Sub-protocol E is a phase I/II trial evaluating the safety and efficacy of capivasertib + venetocolax in combination with dexamethasone in children and AYA with R/R ped ALL/LBL whose tumor present with alterations of the PAM pathway, or lacking any mutations.

开始日期2026-10-01

申办/合作机构

Princess Maxima Centre For Pediatric Oncology

[+2]

ISRCTN99425493

/ Recruiting临床2期IIT

Randomised Phase II open-label window of opportunity trial AKTivate - Identifying target engagement and biomarkers of response, including an imaging biomarker, in participants receiving Capivasertib plus Exemestane and Capivasertib alone in post-menopausal participants with oestrogen receptor positive (ER+) early-stage breast cancer

开始日期2025-10-01

申办/合作机构

Cambridge University Hospitals NHS Foundation Trust

NCT07088913

/ Recruiting临床1期

An Open-label, Fixed-sequence Study to Assess the Effect of Capivasertib on the Pharmacokinetics of Oral Rosuvastatin (a BCRP, OATP1B1 and OATP1B3 Sensitive Substrate) in Healthy Participants

The purpose of the study is to assess the effect of capivasertib on the pharmacokinetics (PK) of oral rosuvastatin in healthy participants.

开始日期2025-07-28

申办/合作机构

AstraZeneca PLC

[+1]

100 项与卡匹色替相关的临床结果

登录后查看更多信息

100 项与卡匹色替相关的转化医学

登录后查看更多信息

100 项与卡匹色替相关的专利（医药）

登录后查看更多信息

399

项与卡匹色替相关的文献（医药）

2025-12-01·CANCER CHEMOTHERAPY AND PHARMACOLOGY

An exposure–safety analysis to support the dosage of the novel AKT inhibitor capivasertib

Article

作者: González-García, Ignacio ; Cullberg, Marie ; Schiavon, Gaia ; Teruel, Carlos Fernandez ; Zhou, Diansong

Abstract:

Purpose:

This study aimed to evaluate capivasertib exposure–response relationships for clinical safety events to support dosage selection.

Methods:

Data from 277 patients with solid tumors participating in three phase 1 studies were analyzed. Capivasertib 80–800 mg was administered as monotherapy orally twice daily (BID) on continuous or intermittent (4 days on, 3 days off [4/3] or 2 days on, 5 days off [2/5]) schedules. Relationships between exposure related metrics (dose, weekly dose, AUC, AUCPWD, Cmax, and Cmin) and probability of safety endpoints (adverse event [AE] leading to dose discontinuation, AE leading to dose modification, serious AE [SAE], AE grade ≥ 3, AE grade ≥ 1, diarrhea AE grade ≥ 2, rash AE grade ≥ 2, hyperglycemia AE grade ≥ 3 and increased blood glucose > 13.9 mmol/L) were evaluated by logistic regression.

Results:

Significant exposure–response relationships were identified for all safety endpoints evaluated, except for AE grade ≥ 1. The analysis suggested that most of the safety endpoints are driven by the total weekly exposure, whereas glucose elevations are driven by the exposure achieved within a dosing interval. The probability of experiencing an AE leading to dose discontinuation, AE leading to dose modification, SAE, AE grade ≥ 3, diarrhea or rash were lower with the 480 mg BID [4/3] schedule than with the 320 mg BID continuous schedule.

Conclusion:

Significant exposure–response relationships were identified for safety endpoints when capivasertib was administered to patients with solid tumors suggesting that the intermittent [4/3] schedule is better tolerated than the continuous schedule due to lower total weekly exposure.

2025-11-01·EClinicalMedicine

Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: a systematic review and network meta-analysis

Article

作者: Chiodini, Paolo ; Dieci, Maria Vittoria ; De Angelis, Carmine ; Pagliuca, Martina ; Botticelli, Andrea ; Cataldo, Maria Letizia ; De Laurentiis, Michelino ; Giordano, Antonio ; Criscitiello, Carmen ; Fordellone, Mario ; Vernieri, Claudio ; Mangiacotti, Federica ; Malorni, Luca ; Caputo, Roberta ; Caltavituro, Aldo ; Grieco, Angela ; Longobardi, Alessandra ; Gerratana, Lorenzo ; Giuliano, Mario ; Buonaiuto, Roberto ; Arpino, Grazia ; Lambertini, Matteo

Background:

In the absence of head-to-head trials, optimal treatment sequencing following disease progression on a CDK4/6 inhibitor (CDK4/6i) combined with endocrine therapy (ET) in hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer (mBC) remains challenging. To address this gap, we conducted a systematic review and network meta-analysis (NMA) to provide evidence-based guidance for treatment selection in this setting.

Methods:

We identified randomized phase II-III trials involving HR+/HER2- mBC patients whose tumors progressed on CDK4/6i-based therapy, published between January 1, 2014 and June 6, 2025 (PROSPERO n° CRD42024604417). Hazard ratios (HRs) for progression-free survival (PFS) were extracted from published data and analyzed using a frequentist random-effects model. Subgroup analyses were performed based on the duration of CDK4/6i treatment and the presence of ESR1 or PI3K/PTEN/AKT pathway alterations. Treatments were compared with conventional ET or chemotherapy and ranked using the P-score metric. Confidence in network estimates was evaluated using the CINeMA framework. Safety data, including grade ≥3 adverse events (AEs) and treatment discontinuation, were descriptively analyzed.

Findings:

Twenty-eight randomized trials (n = 6544) were included in the NMA. Sapanisertib plus fulvestrant provided the greatest PFS benefit (HR 0.34, 95% CI 0.14-0.82) but had a high discontinuation rate (>15%). Among the approved therapies, ribociclib plus ET (HR 0.57, 95% CI 0.39-0.84), capivasertib plus fulvestrant (HR 0.62, 95% CI 0.51-0.75), and elacestrant (HR 0.70, 95% CI 0.55-0.89) demonstrated superior efficacy. Elacestrant was most effective in patients with ESR1-mutant tumors and among patients with prolonged prior CDK4/6i exposure. Ipatasertib and alpelisib showed the greatest benefits in patients with PI3K/PTEN/AKT alterations. Antibody-drug conjugates (ADCs), such as trastuzumab deruxtecan and sacituzumab govitecan, outperformed standard chemotherapy, albeit with higher toxicity.

Interpretation:

Combinations of targeted agents with ET or novel endocrine agents such as oral selective estrogen receptor degraders (SERDs) demonstrated favorable efficacy and safety profiles in biomarker-selected populations, supporting a shift toward biomarker-driven treatment algorithms. In endocrine-resistant diseases that require chemotherapy, ADCs are the most effective therapeutic option.

Funding:

We acknowledge financial support under the National Recovery and Resilience Plan (NRRP), Mission 4, Component 2, Investment 1.1, Call for tender No. 1409 published on 14.9.2022 by the Italian Ministry of University and Research (MUR), funded by the European Union - NextGenerationEU - Project Title: Identifying predictive/prognostic biomarkers and mechanisms underlying resistance to CDK4/6 inhibition beyond progression in hormone receptor-positive/HER2-negative metastatic breast cancer - CUP E53D23020460001 (Project code: P2022FK2J8, ERC panel: LS7, Principal Investigator: Carmine De Angelis). Grant Assignment Decree No. 1369 adopted on 01.09.2023 by the Italian Ministry of University and Research (MUR).

2025-10-01·LEUKEMIA

Superoxide-mediated phosphorylation and stabilization of Mcl-1 by AKT underlie venetoclax resistance in hematologic malignancies

Article

作者: Iskandar, Kartini ; Cheung, Alice M S ; Davids, Matthew S ; Lim, Rachel H F ; Wang, Yuhan ; Pervaiz, Shazib ; Lai, Jolin X H ; Raman, Deepika ; Leong, Benedict J ; Wu, Catherine J ; Chng, Wee Joo ; Chong, Stephen J F ; Wang, Chuqi ; Guièze, Romain ; Chuah, Charles

Abstract:

Resistance to the Bcl-2-specific inhibitor, Venetoclax (VEN), poses a therapeutic challenge in the management of chronic lymphocytic leukemia and acute myeloid leukemia. Although VEN resistance has been linked to Mcl-1 upregulation, thereby switching survival dependence from Bcl-2 to Mcl-1, the mechanism underlying increased Mcl-1 expression remains elusive. Given that changes in cellular redox state affect cancer cell fate, we investigated the crosstalk between intracellular redox milieu and Mcl-1 upregulation in VEN-resistant cells. Results show that increased Mcl-1 protein levels in VEN-resistant hematologic malignant cells are associated with elevated intracellular superoxide (O2.−) levels. Validating that, augmenting intracellular O2.− in VEN-sensitive cells increases Mcl-1 phosphorylation at threonine-163 (T163pMcl-1) and protein stability via reduced Mcl-1 ubiquitination and degradation. Furthermore, redox-activated AKT/PKB is implicated in O2.−-induced T163pMcl-1, as reducing intracellular O2.− or inhibiting AKT significantly decreases T163pMcl-1 and Mcl-1 accumulation, which amplifies mitochondrial apoptotic priming and restores VEN sensitivity. Importantly, combination therapy with AKT inhibitor, capivasertib, and VEN reduced VEN-resistant cells systemically and prolonged survival in a murine model. Collectively, a novel redox-dependent mechanism of Mcl-1 stability is demonstrated for the acquisition of VEN resistance, which has therapeutic implications for employing redox modulating strategies and AKT inhibitors against VEN-resistant hematologic malignancies.

374

项与卡匹色替相关的新闻（医药）

2025-10-15

·医脉通

分层论治，精准突破：2025 ESMO转移性乳腺癌指南中HR阳性/HER2阴性亚型治疗策略解析

前言近期，欧洲肿瘤内科学会（ESMO）于Annals of Oncology发布了转移性乳腺癌（MBC）临床实践指南系统治疗更新1。激素受体（HR）阳性/人表皮生长因子受体2（HER2）阴性作为最常见的MBC亚型，《ESMO转移性乳腺癌指南》2围绕其临床异质性（内分泌敏感性、疾病进展状态、器官功能风险）与生物学异质性（基因突变状态），构建了覆盖全病程的分层治疗体系。本文聚焦该亚型的治疗核心推荐，梳理一线治疗、疾病进展后治疗及特殊场景治疗的完整路径，为临床实践提供清晰指导。固定布局工具条上设置固定宽高背景可以设置被包含可以完美对齐背景图和文字以及制作自己的模板一线治疗：以内分泌敏感性为核心分层，锁定靶向联合核心方案 HR阳性/HER2阴性MBC一线治疗的核心逻辑是“内分泌敏感性分层+生物标志物指导”，指南划分三类临床场景，为每类场景提供对应的治疗策略。 ► 内分泌敏感/未治疗人群：芳香化酶抑制剂（AI）+CDK4/6抑制剂为标准此类人群定义为“初发转移性乳腺癌（de novo MBC）”或“早期乳腺癌术后辅助内分泌治疗（ET）结束＞12个月复发”，指南推荐以“AI+CDK4/6抑制剂”为核心方案。图1. 内分泌敏感/未治疗人群推荐一线治疗路径2 ► 内分泌耐药人群：PIK3CA突变状态主导方案选择此类人群定义为“早期乳腺癌术后辅助ET期间复发”或“辅助ET结束≤12个月复发”，指南推荐先检测PIK3CA状态（证据等级I，推荐级别A），再依据PIK3CA突变状态制定差异化方案，同时保留经典联合方案选项。图2. 内分泌耐药人群推荐一线治疗路径2 ► 内脏危象人群：快速控制病情为核心，化疗与ADC药物互补此类人群表现为“即将发生器官衰竭（内脏危象）”，指南推荐以“化疗优先，ADC药物补充”为原则。图3. 内脏危象人群推荐一线治疗路径2 ► HR阳性/HER2阴性MBC一线治疗方案2 注：T-DXd：德曲妥珠单抗不同HR阳性/HER2阴性MBC患者对ET的响应存在显著差异，指南以内分泌敏感性与治疗靶点等作为分层维度，划分三类临床场景并匹配一线治疗方案，兼顾标准疗效与实践灵活性，精准匹配治疗需求：对于内分泌敏感/未治疗人群，因其肿瘤仍保留对ET的响应能力，“AI+CDK4/6抑制剂”成为标准方案。经PALOMA-23、MONALEESA-24和MONARCH-35研究等III期研究验证，AI+CDK4/6抑制剂联合方案较单药AI能显著延长患者中位无进展生存期（PFS），且ESMO-MCBS评分提示其“高临床获益”。而当CDK4/6抑制剂不可及等特殊情况出现时，可“先单药ET再序贯氟维司群+CDK4/6抑制剂”，适配药物可及性差异，避免治疗中断。对于内分泌耐药人群，指南优先推荐检测PIK3CA状态，以靶向耐药驱动基因。PIK3CA是该亚型中最常见的突变基因之一，其突变可使PI3K/AKT/mTOR通路异常激活，促进肿瘤细胞的生长和抗凋亡能力，导致乳腺癌ET耐药。III期INAVO120研究显示，“氟维司群+哌柏西利+伊那利塞”三联方案通过“雌激素受体降解+PI3Kα抑制+CDK4/6抑制”三通路阻断逆转耐药6，因此可作为PIK3CA突变患者的优先选择。针对内脏危象人群，指南推荐采用化疗或ADC方案治疗。化疗药物起效较快，能快速缓解器官压迫、挽救功能；而肿瘤负荷高者可联用贝伐珠单抗增强疗效。疾病进展后治疗：双路径分层，兼顾内分泌潜力与新型药物应用 HR阳性/HER2阴性MBC发生疾病进展（PD）后的治疗路径，分为“适合ET±靶向治疗（TT）”与“不适合ET±TT”两类，每类路径均结合患者及疾病特征、生物标志物状态与既往治疗史，提供相应的推荐方案。 ► 适合ET±TT人群：基于生物标志物匹配靶向方案，明确无靶点时的备选策略此类人群治疗推荐以“生物标志物指导靶向联合”为核心：图4. PD后“适合ET±TT”患者治疗路径2 ► 不适合ET±TT人群：化疗与ADC药物分场景推荐，明确HER2低表达/超低表达人群方案此类人群治疗推荐以“化疗为基础，ADC药物为重要补充”：图5. PD后“不适合ET±TT”患者治疗路径2 ► HR阳性/HER2阴性MBC疾病进展后治疗方案2 注：T-DXd：德曲妥珠单抗；SG：戈沙妥珠单抗；Dato-DXd：德达博妥单抗指南创新性引入“适合ET±TT”与“不适合ET±TT”两类路径，用于指导PD后的治疗选择，核心依据患者及疾病特征（如既往基于ET方案的疾病进展时间，time to PD），精准判定从ET方案转换至非ET方案的最佳时机，确保治疗决策贴合个体病情差异。适合ET±TT人群需结合既往ET疗效（如PFS时长）与疾病状态（进展缓慢、无症状）综合判定，治疗以“生物标志物指导靶向联合”为核心：基于CAPItello-291研究7证据，携带一种或多种PIK3CA/AKT1/PTEN改变者推荐“氟维司群+卡匹色替”方案，通过AKT抑制阻断耐药通路，显著延长患者PFS；ESR1突变者优先选用Elacestrant，针对性降解雌激素受体，从而抑制雌激素依赖性肿瘤细胞的增殖8；胚系BRCA1/2/PALB2突变者采用PARP抑制剂，利用“合成致死”效应靶向DNA修复缺陷；无明确靶点者可选择更换ET±CDK4/6抑制剂、依西美坦+依维莫司等方案，平衡疗效与耐受性。不适合ET±TT的人群，多表现为疾病快速进展（如PFS短）、症状明显，ET获益有限。对于未接受过MBC阶段化疗者，以化疗为基础，肿瘤负荷高者可联用贝伐珠单抗增强疗效；对于接受过1-2线化疗者，HER2低表达人群仍可使用T-DXd，非此类人群用SG、Dato-DXd等Trop-2靶向ADC，借助精准靶向肿瘤细胞发挥作用；此外，对于HER2低表达且辅助化疗后快速进展的患者，可跨线使用T-DXd，若T-DXd治疗进展，序贯SG，针对不同靶点以克服交叉耐药，为患者带来持续治疗获益9。小结《ESMO转移性乳腺癌指南》进一步完善了HR阳性/HER2阴性MBC“分层论治、精准靶向”的体系：需先通过“内分泌敏感性+器官功能状态”划分治疗场景，再结合“PIK3CA/ESR1/BRCA等基因突变状态”选择具体方案，同时关注药物可及性与患者耐受性。未来，随着更多生物标志物的发现与新型药物的研发，该亚型的治疗将更加精准化，为患者带来更贴合个体需求的治疗选择。参考资料： [1] Trapani D,et al. Ann Oncol. 2025 Aug 12. DOI:10.1016/j.annonc.2025.07.017 [2] https://www.esmo.org/guidelines/living-guidelines/esmo-living-guideline-metastatic-breast-cancer/hr-positive-her2-negative-metastatic-breast-cancer [3] Slamon DJ, et al. J Clin Oncol. 2024 Jan 22:JCO2300137. doi: 10.1200/JCO.23.00137. [4] Hortobagyi GN, et al. Ann Oncol. 2018; 29(7): 1541-1547. [5] Johnston S. NPJ Breast Cancer. 2019 Jan 17;5:5. [6] Turner NC, et al. N Engl J Med. 2024;391(17):1584-1596. doi:10.1056/NEJMoa2404625 [7] Turner NC, et al. N Engl J Med. 2023;388(22):2058-2070. [8] Bidard FC, et al. J Clin Oncol. 2022;40(28):3246-3256. doi:10.1200/JCO.22.00338 [9] Huppert, L.A., et al. npj Breast Cancer 11, 34 (2025). 本材料由阿斯利康提供，仅供医疗卫生专业人士参考。以上指南内容涉及未获批产品/适应症，阿斯利康不推荐任何未获批药品/适应症的使用。审批编号：CN-168734 过期日期：2026-03-29 撰写：KIKI 审校：KIKI 排版：Mythero 执行：Zelda 本平台旨在为医疗卫生专业人士传递更多医学信息。本平台发布的内容，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。如该等信息被用于了解医学信息以外的目的，本平台不承担相关责任。本平台对发布的内容，并不代表同意其描述和观点。若涉及版权问题，烦请权利人与我们联系，我们将尽快处理。

临床结果临床3期抗体药物偶联物临床2期

2025-10-15

·医脉通

ESMO 2025开幕在即！一文速览肿瘤领域“风向标”级研究进展

// 前言 // 欧洲肿瘤内科学会（ESMO）年会是全球肿瘤学领域最具影响力的学术盛会之一，每年都会公布多项改变临床实践的重要研究成果，指引着全球肿瘤治疗的方向和趋势。今年ESMO年会将于柏林当地时间10月17日正式启幕，带来为期5日的学术盛宴。在本届盛会中，阿斯利康携多项核心肿瘤领域的最新研究成果闪亮登场，涵盖乳腺癌、肺癌、消化道肿瘤、泌尿肿瘤及妇科肿瘤等多个关键疾病领域，其中不乏将重塑临床实践格局的重磅研究，包括为双双入选主席研讨会环节的DESTINY-Breast11（DB11）、DESTINY-Breast05（DB05）研究、EGFR突变晚期非小细胞肺癌（NSCLC）带来生存突破的FLAURA2研究更新等。这些成果不仅预示治疗范式的演进，更将推动全球肿瘤治疗格局的更新与升级，是本届ESMO不容错过的科研亮点。接下来，我们将分瘤种一览阿斯利康在此次ESMO年会中的最新动态。砥砺前行，引领乳腺癌治疗新风向本次ESMO年会中，德曲妥珠单抗（T-DXd）、Camizestrant、德达博妥单抗（Dato-DXd）、卡匹色替等药物在乳腺癌领域表现亮眼，多项重磅研究数据即将揭晓。其中，尤为引人瞩目的是T-DXd在HER2阳性早期乳腺癌领域的“双子星”——DB11、DB05研究均成功入选“主席研讨会”环节，彰显其卓越学术价值与临床影响力。其中，聚焦新辅助治疗中的DB11研究对比了T-DXd单药、T-DXd序贯THP与ddAC序贯THP方案在HER2阳性早期乳腺癌新辅助治疗中的疗效与安全性。研究提示与ddAC序贯THP方案相比，T-DXd序贯THP方案显示出具有临床意义和统计学意义的病理完全缓解率提升，并改善了安全性，为T-DXd在HER2阳性早期乳腺癌新辅助治疗中的应用提供了关键循证。与此同时，DB05研究头对头比较了T-DXd与恩美曲妥珠单抗（T-DM1）在未达病理完全缓解（non-pCR）HER2阳性早期乳腺癌中的疗效与安全性。日前，DB05研究已报阳性结果，即与T-DM1相比，T-DXd在无浸润性疾病生存期（iDFS）方面取得了具有高度统计学意义和临床意义的改善。DB05、DB11的双阳性结果意味着T-DXd成功实现了从晚期到早期的跨越，将为HER2阳性早期乳腺癌患者树立“治愈”新标杆。此外，已在HER2阳性乳腺癌一线治疗实现无进展生存期（PFS）突破的DESTINY-Breast09研究也成功入选LBA，此次大会也将公布其关键亚组的额外分析数据，为T-DXd在一线治疗的应用提供进一步证据支持。 TROPION-Breast02（TB02）研究作为Dato-DXd在三阴性乳腺癌领域的首个III期研究，对比了Dato-DXd与化疗在不适合免疫治疗的晚期三阴性乳腺癌一线治疗中的疗效与安全性。本届ESMO大会上，TB02研究入选LBA，将首次公布其主要研究结果，为Dato-DXd用于不适合免疫治疗的晚期三阴性乳腺癌一线治疗奠定关键循证基础。除以上研究外，在HR阳性/HER2阴性领域，SERENA-6研究已证实了循环肿瘤DNA（ctDNA）监测ESR1突变指导治疗转换为Camizestrant的疗效和安全性，此次ESMO上将公布SERENA-6研究的患者报告结局，进一步支持了这一治疗新策略的临床应用，为HR阳性/HER2阴性乳腺癌的临床实践注入更多活力；并且卡匹色替在HR阳性/HER2阴性晚期乳腺癌领域的关键性III期研究，CAPItello-291研究中不同经治线数的亚组分析数据也将登陆ESMO，结果提示与安慰剂+氟维司群相比，卡匹色替+氟维司群可在一线、二线或既往接受过CDK4/6抑制剂的二线人群中为患者带来一致的PFS获益，为存在PIK3CA/AKT1/PTEN基因改变的HR阳性/HER2阴性乳腺癌个体化、精准化诊疗供重要指导。乳腺癌领域重要研究（上下滑动查看更多信息）摘要号：291O 标题：DESTINY-Breast11: Neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC) 讲者：Nadia Harbeck 报告时间：10月18日16:30 - 16:42（柏林当地时间）报告地点：Berlin Auditorium - Hub 27 摘要号：LBA1 标题：Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with high-risk human epidermal growth factor receptor 2–positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy (tx): Interim analysis of DESTINY-Breast05 讲者：Charles E. Geyer 报告时间：10月18日16:52 - 17:04（柏林当地时间）报告地点：Berlin Auditorium - Hub 27 摘要号：LBA18 标题：Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC): additional analyses of DESTINY-Breast09 in key subgroups of interest 讲者：Sibylle Loibl 报告时间：10月19日08:30 - 08:40（柏林当地时间）报告地点：Munich Auditorium - CityCube B 摘要号：LBA21 标题：First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase 3 TROPION-Breast02 trial 讲者：Rebecca A. Dent 报告时间：10月19日09:25 - 09:35（柏林当地时间）报告地点：Munich Auditorium - CityCube B 摘要号：486MO 标题：Patient-reported outcomes (PROs) from the SERENA-6 trial of camizestrant (CAMI) + CDK4/6 inhibitor (CDK4/6i) for emergent ESR1m during first-line (1L) endocrine-based therapy and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC) 讲者：Erica Mayer 报告时间：10月20日10:25 - 10:30（柏林当地时间）报告地点：Munich Auditorium - CityCube B 摘要号：526P 标题：Capivasertib plus fulvestrant as first and second-line endocrine-based therapy in PIK3CA/AKT1/PTEN-altered hormone receptor-positive advanced breast cancer: Subgroup analysis from the phase 3 CAPItello-291 trial 讲者：Hope S. Rugo 多点开花，引领NSCLC临床治疗全方位突破在NSCLC领域，EGFR作为最受关注的驱动基因靶点之一，本届ESMO大会公布了FLAURA2、SACHI及ADAURA相关回顾性分析等多项关键研究的最新数据，全面覆盖了EGFR突变早期与晚期NSCLC的临床治疗进展。在EGFR突变晚期NSCLC的一线治疗方面，FLAURA2研究既往数据显示，相较于奥希替尼单药治疗，奥希替尼联合化疗可为全人群患者带来具有显著统计学和临床意义的OS获益，中位OS近4年，重新定义了EGFR突变晚期NSCLC患者的一线治疗标准。本次ESMO大会将公布FLAURA2研究中不良预后人群的探索性OS分析结果，进一步阐释奥希替尼联合化疗在伴有不良预后因素患者中的临床应用价值。在EGFR阳性晚期NSCLC的后线治疗方面，SACHI研究此前在ASCO会议上首次发布数据，为EGFR-TKI进展后患者的后续治疗提供了高级别的循证医学证据，助力临床诊疗策略的优化。此次ESMO公布的SACHI研究ctDNA分析显示，赛沃替尼联合奥希替尼组患者ctDNA中EGFR突变的清除率更高，且ctDNA中EGFR突变的清除与更长的 PFS 相关。该发现进一步验证了赛沃替尼与奥希替尼双靶向联合治疗的疗效优势，同时凸显了ctDNA动态监测在疗效评估和疾病管理中的潜在临床价值。在EGFR突变早期NSCLC治疗领域，ADAURA研究确立了奥希替尼辅助治疗的标准地位。然而，对于接受辅助治疗后出现复发或转移的患者，目前尚缺乏统一的标准治疗方案。本届ESMO大会上，我国学者报告了一项基于ADAURA研究的单中心回顾性分析，探讨了奥希替尼再挑战策略的可行性。结果显示，接受辅助奥希替尼治疗发生复发后并经活检确认具有EGFR突变的患者，再次接受奥希替尼一线治疗仍具有临床疗效，这可能为该类患者的临床管理提供新的思路与方向。驱动基因阴性NSCLC治疗领域，本届大会将公布ARTEMIDE-01研究的最新数据。该研究此前已初步显示，PD-1/TIGIT双特异性抗体Rilvegostomig在免疫检查点抑制剂（CPI）经治或初治患者中均具有令人鼓舞的临床应用潜力。在本次ESMO大会上公布的ARTEMIDE-01研究最新结果显示，在CPI初治患者中，无论PD-L1表达水平高低或既往是否接受过化疗，Rilvegostomig均能为患者带来深度且持久的肿瘤缓解，并展现出令人鼓舞的生存获益和良好的安全性。肺癌领域重要研究（上下滑动查看更多信息）摘要号：LBA77 标题：FLAURA2: exploratory overall survival (OS) analysis in patients (pts) with poorer prognostic factors treated with osimertinib (osi) ± platinum-pemetrexed chemotherapy (CTx) as first-line (1L) treatment (tx) for EGFR-mutated (EGFRm) advanced NSCLC 讲者：Pasi A. Jänne 报告时间：10月17日16:56 - 17:06（柏林当地时间）报告地点：Berlin Auditorium - Hub 27 摘要号：1954P 标题：ctDNA analysis in phase III SACHI trial: Savolitinib (savo) plus osimertinib (osi) versus chemotherapy (chemo) in MET-amplified (METamp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI) 讲者：Yongfeng Yu 摘要号：2049eP 标题：Osimertinib rechallenge after relapse following adjuvant osimertinib: A single center retrospective analysis of ADAURA 讲者：Weiwei Wang 摘要号：1853MO 标题：Efficacy and safety of rilvegostomig, an anti-PD-1/TIGIT bispecific antibody, for checkpoint inhibitor (CPI)-naïve metastatic non-small cell lung cancer (mNSCLC): ARTEMIDE-01 讲者：Byoung Chul Cho 报告时间：10月20日10:25 - 10:30（柏林当地时间）报告地点：Berlin Auditorium - Hub 27 破局而生，赋能消化道肿瘤诊疗在本届ESMO年会的消化道肿瘤领域，多款新药与创新疗法强势亮相，覆盖肝胆肿瘤、胃癌等重要疾病领域。其中，HIMALAYA、MATTERHORN、DESTINY-Gastric04(DG04)、DESTINY-Gastric06(DG06)等研究为消化道肿瘤患者带来全新治疗选择，不仅有望进一步完善临床诊疗路径，更将推动该领域精准治疗迈入高质量发展新阶段。在不可切除的晚期肝细胞癌（uHCC）领域，HIMALAYA研究持续刷新治疗高度。作为当前*uHCC一线治疗中首个报道 5 年总生存期（OS）随访数据的III期研究，其成果已成为 uHCC领域的重要标杆。本届大会首次公布了该研究的6年OS结果，对中国扩展队列与全球队列的汇总分析显示，相较索拉非尼，度伐利尤单抗联合Tremelimumab和度伐利尤单抗治疗均展现出更优的长期生存获益且安全性可控，进一步巩固了其在uHCC一线治疗中的地位，同时为中国人群应用提供疗效与安全性的医学证据。在胃癌领域，作为目前*全球首个证实局晚期胃癌围术期免疫治疗长期疗效获益的III期临床试验，MATTERHORN研究以“度伐利尤单抗联合 FLOT 方案”打破传统围术期治疗局限，成功揭开胃癌围术期治疗的新篇章。本届ESMO年会提交论文报告环节的口头汇报进一步更新了该研究中的最终总生存期（OS）和病理结局相关的无事件生存期（EFS）等核心数据，为这一方案的临床应用提供更详实的循证支持。此外，针对HER2阳性晚期胃癌这一难治亚型，DESTINY-Gastric04与DESTINY-Gastric06两项研究持续发力，引领胃癌领域革命性突破。2025 ASCO公布的DESTINY-Gastric04研究证实，相较对照组（雷莫西尤单抗+紫杉醇，即RAM + PTX），德曲妥珠单抗（T-DXd）二线治疗具有显著的生存获益（mOS：14.7个月 vs11.4个月；mPFS：6.7 个月 vs 5.6 个月；2年OS率：13.9% vs 9.0%），同时ORR、DCR和DOR（44.3% vs 29.1%；91.9% vs 75.9%；7.4个月 vs 5.3个月）也显著提升，为 HER2阳性晚期胃癌二线治疗树立新标杆。ESMO Asia 2024公布的DESTINY-Gastric06研究最终分析结果显示，在HER2阳性晚期胃癌中国患者三线治疗中，T-DXd组mPFS为5.7个月，ORR为28.8%，中位DOR为6.7个月，DoR为6.7个月，mOS为11.1个月，敏感性分析后延长至 12.4 个月（95% CI：7.9, 14.5)，突破1年大关，进一步验证其持久的抗肿瘤活性。本届ESMO年会对这两项研究进行了更新：DESTINY-Gastric04结果显示，在HER2阳性晚期GC/GEJA的二线治疗中，T-DXd相较于RAM+PTX具有临床意义的疗效改善，且未发现新的安全性问题；DESTINY-Gastric06结果显示，在既往接受过多种抗HER2治疗的中国HER2阳性晚期GC/GEJA患者中，T-DXd（6.4 mg/kg）展现出具有统计学意义的临床疗效，可成为该人群的治疗选择。此外，亚组分析进一步显示，T-DXd治疗的乙型肝炎病毒再激活风险低，因此也适用于有HBV病史或非活动性慢性HBV感染的HER2阳性晚期GC/GEJA患者。综上，T-DXd 有望为HER2阳性晚期胃癌患者的精准治疗提供更优化的方案选择。消化道领域重要研究（上下滑动查看更多信息）摘要号：LBA81 标题：Final overall survival (OS) and the association of pathological outcomes with event-free survival (EFS) in MATTERHORN: A randomised, phase III study of durvalumab (D) plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric / gastroesophageal junction (G / GEJ) adenocarcinoma 讲者：Josep Tabernero 报告时间：10月17日14:00 - 14:10（柏林当地时间）报告地点：Hamburg Auditorium - CityCube A 摘要号：737MO 标题：Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic colorectal cancer (mCRC): Final analysis of DESTINY-CRC02, a randomized, phase II trial 讲者：Kanwal Raghav 报告时间：10月19日15:15 - 15:20（柏林当地时间）报告地点：Cologne Auditorium - CityCube A 摘要号：80MO 标题：Durvalumab (D) plus tremelimumab (T) in advanced biliary tract carcinoma (BTC) patients (Pts) after failure of platinum-based chemotherapy (CTx): Final results of the IMMUNOBIL GERCOR D18-1 PRODIGE-57 phase II trial 讲者：Matthieu Delaye 报告时间：10月20日08:58 - 09:03（柏林当地时间）报告地点：Bonn Auditorium - Hall 7.1c 摘要号：1494P 标题：Pooled efficacy and safety outcomes with tremelimumab plus durvalumab in participants (pts) with unresectable hepatocellular carcinoma (uHCC) from the combined China extension and global cohorts in the phase III HIMALAYA study 讲者：Bruno Sangro 报告时间：10月18-19日12:00 - 12:45（柏林当地时间）报告地点：Hall 25 摘要号：2099P 标题：Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) plus paclitaxel (PTX) in second-line (2L) treatment of patients (pts) with HER2+ unresectable/metastatic gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): Additional data from DESTINY-Gastric04 (DG-04) 讲者：Filippo Pietrantonio 报告时间：10月18-19日12:00 - 12:45（柏林当地时间）报告地点：Hall 25 摘要号：2105P 标题：Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA) who received prior anti-HER2 treatment (Tx) other than / in addition to trastuzumab in DESTINY-Gastric06 (DG-06) 讲者：Zhi Peng 报告时间：10月18-19日12:00 - 12:45（柏林当地时间）报告地点：Hall 25 摘要号：2175P 标题：Risk of hepatitis B virus reactivation (HBVr) in patients (pts) with past or resolved HBV or inactive chronic HBV infection treated with trastuzumab deruxtecan (T-DXd) in DESTINY-Gastric06 (DG-06) 讲者：Lin Shen 报告时间：10月18-19日12:00 - 12:45（柏林当地时间）报告地点：Hall 25 多维覆盖，靶免重塑泌尿肿瘤治疗新纪元在本届ESMO年会上，泌尿肿瘤领域迎来多项重磅研究数据的公布。其中，CAPltello-281、PETRANHA、POTOMAC、NIAGARA等研究为患者带来全新治疗选择，从晚期前列腺癌的精准靶向到膀胱癌的免疫联合治疗策略，一系列创新疗法正强势推动临床实践变革。在前列腺癌中，PTEN基因是变异率最高的抑癌基因之一。CAPltello-281研究作为一项针对PTEN缺陷型转移性激素敏感性前列腺癌（mHSPC）的全球III期临床试验，成功证实了蛋白激酶B（AKT）抑制剂卡匹色替在该人群中的治疗价值。本届大会更新了该项研究的结果，相比安慰剂+阿比特龙组，卡匹色替+阿比特龙组的影像学无进展生存期（rPFS）显著延长（33.2个月 vs. 25.7个月，HR 0.81，P=0.034），达到了其主要研究目标。这一突破性进展不仅破解了PTEN缺陷型新诊断mHSPC的临床难题，更有望重塑晚期前列腺癌的治疗格局，成为精准医学实践的重要范本。 PETRANHA研究则聚焦于转移性前列腺癌的联合治疗策略，创新性地探索多聚腺苷二磷酸核糖聚合酶抑制剂（PARPi）saruparib与雄激素受体通路抑制剂（ARPI）的协同增效作用，实现对肿瘤的双重精准打击。本届大会所揭晓的首次中期疗效分析结果提示，Saruparib+ARPI联合治疗在mHSPC和既往未接受过ARPI治疗的转移性去势抵抗性前列腺癌（mCRPC）患者中，均表现出良好的安全性和初步疗效。该结果有望为“1+1＞2”的这一创新疗法在HRR基因突变人群中的临床获益提供关键的证据。今年5月，度伐利尤单抗联合卡介苗（BCG）方案已在III期临床试验 POTOMAC中显示出对高风险非肌层浸润性膀胱癌（NMIBC）患者无病生存期（DFS）具有统计学显著和临床意义的改善。本届大会上的最终分析数据将进一步验证该联合策略的卓越潜力与持久获益，有望为高危NMIBC的临床管理提供坚实的破局之策。随着研究的深入与临床经验的积累，肌层浸润性膀胱癌（MIBC）的围术期免疫治疗已不再局限于术后辅助，NIAGARA研究重点评估了度伐利尤单抗联合新辅助化疗的应用价值。该研究不仅关注传统生存终点，本届大会更是报道了健康相关生活质量（HRQoL）的数据。研究结果显示，在接受新辅助化疗联合根治性膀胱切除术的基础上，围手术期加用度伐利尤单抗治疗，不仅为患者带来具有临床意义的无事件生存期（EFS）和OS获益，而且不会对患者报告的HRQoL造成负面影响。这进一步支持该方案成为MIBC的一种新的治疗选择，为在围术期实现疗效与患者生活质量的平衡提供了高级别循证依据。泌尿肿瘤领域重要研究（上下滑动查看更多信息）摘要号：2383O 标题：A Phase 3 study of capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC): CAPItello-281 讲者：Karim Fizazi 报告时间：10月19日11:19 - 11:29（柏林当地时间）报告地点：Hamburg Auditorium - CityCube A 摘要号：2384MO 标题：First interim efficacy analysis of the Phase 1/2 PETRANHA trial of saruparib + androgen receptor pathway inhibitors (ARPI) in patients (pts) with metastatic prostate cancer (mPC) 讲者：Arun A. Azad 报告时间：10月17日14:35 - 14:40（柏林当地时间）报告地点：Heidelberg Auditorium - Hall 6.2 摘要号：LBA108 标题：Durvalumab (D) in combination with bacillus Calmette-Guérin (BCG) for BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC): final analysis of the phase 3, open-label, randomised POTOMAC trial 讲者：Maria De Santis 报告时间：10月17日14:10 - 14:20（柏林当地时间）报告地点：Dortmund Auditorium - Hall 7.1a 摘要号：3069MO 标题：Health-related quality of life (HRQoL) outcomes from the NIAGARA trial of perioperative durvalumab (D) plus neoadjuvant chemotherapy (NAC) in muscle-invasive bladder cancer (MIBC) 讲者：Michiel S. Van der Heijden 报告时间：10月17日16:00- 16:05（柏林当地时间）报告地点：Karlsruhe Auditorium - Hall 5.2 全域布局，靶免疗法助力妇科肿瘤精准之路在本届ESMO大会上，妇科肿瘤领域同样捷报频传，多项研究围绕卵巢癌、子宫内膜癌等妇科肿瘤，在精准靶向与免疫联合治疗方面取得关键进展。L-MOCA、FONTANA、DUO-E、GINECO UTOLA及DESTINY-PanTumor02等研究的成果集中发布，不仅为不同阶段的患者带来了新的生存希望，更标志着妇科肿瘤诊疗正全面迈入个体化、精准化的新阶段。在卵巢癌领域，L-MOCA研究（NCT03534453）迎来最终OS数据的揭晓。作为一项在亚洲开展的奥拉帕利单药维持治疗铂敏感复发性卵巢癌（PSROC）的III期研究，L-MOCA研究既往公布的期中分析结果显示，奥拉帕利显著改善了全人群患者的PFS。本次ESMO大会揭晓的最终OS结果证实，无论BRCA突变状态如何，奥拉帕利在亚洲PSROC患者中均显示出具有潜力的OS获益，在既往接受多化疗的亚组中同样取得了明确获益，且其安全性特征持续保持良好耐受性，进一步夯实了奥拉帕利作为PSROC全人群维持治疗标准选择的循证医学证据。 FONTANA（NCT05797168）是一项AZD5335[靶向叶酸受体α（FRα）的ADC]在铂耐药复发性卵巢癌（PROC）患者中的首次人体研究。既往研究显示，AZD5335单药治疗PROC总缓解率为34.2%，表现出较好的抗肿瘤活性。本次大会公布的结果再次表明，AZD5335具有可控的安全性特征，且在剂量优化阶段所选择的所有剂量水平中，以及在FRα高表达与低表达的肿瘤患者中，均展现出具有竞争力的疗效。该数据将为AZD5335未来用于卵巢癌及其他实体瘤的单药治疗与联合治疗研究点亮新曙光。在子宫内膜癌领域，精准化的探索正向纵深发展。DUO-E研究评估了在化疗基础上联合度伐利尤单抗并序贯度伐利尤单抗±奥拉帕利维持治疗的疗效。其中，化疗联合度伐利尤单抗、后续序贯度伐利尤单抗的最大获益见于错配修复缺陷型（dMMR）亚组人群；而在错配修复正常型（pMMR）亚组人群中，加用奥拉帕利可进一步提升获益。本次ESMO大会将公布基于高肿瘤突变负荷（TMB-H）的预设探索性分析数据，结果表明，在化疗基础上加用度伐利尤单抗同样可带来具有临床意义的PFS改善，为晚期子宫内膜癌的精准分型与治疗策略选择提供关键洞见。此外，IIb期GINECO UTOLA试验评估了奥拉帕利一线维持治疗晚期/转移性子宫内膜癌患者的疗效与安全性，本次ESMO将公布三项辅助分析结果，深化了子宫内膜癌的分子分型，为个体化免疫治疗策略奠定了重要基础。其中一项研究成功验证了转录组谱分析可细化p53野生型患者的预后并指导个体化治疗；另两项与CARPEM队列的联合分析，揭示了子宫内膜癌的免疫微环境在不同分子亚组间、亚组内及不同分期间与预后相关的免疫微环境异质性，并利用转录组谱分析揭示了更识别出p53异常/GIS低表达肿瘤中微管抑制剂偶联抗体的潜在治疗靶点及差异化的免疫逃逸机制。 DESTINY-PanTumor02研究作为探索T-DXd在多种HER2表达实体瘤中应用的II期篮子试验，其妇瘤领域的分析结果异常亮眼。子宫内膜癌、宫颈癌和卵巢癌的ORR分别高达57.5%、50.0%和45.0%，具有临床意义的PFS和OS令人鼓舞。本次ESMO大会将公布的最终分析，与初步分析结果一致，T-DXd在经治HER2表达实体瘤患者中显示出持久抗肿瘤活性（全人群ORR 37.5%，中位PFS 6.9个月），其中IHC 3+患者获益更显著（ORR 52.3%，中位PFS 9.7个月），且在HER2扩增人群及多种基因突变亚组中均观察到活性，安全性特征与已知一致，进一步证实T-DXd可作为HER2表达阳性实体瘤的有效治疗选择。妇科肿瘤领域重要研究（上下滑动查看更多信息）摘要号：1090P 标题：Final overall survival (OS) analysis of L-MOCA: olaparib maintenance monotherapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) 讲者：Qinglei Gao 摘要号：1065MO 标题：First-in-human study of AZD5335, a folate receptor α (FRα)-targeted antibody-drug conjugate, in patients with platinum-resistant recurrent ovarian cancer 讲者：Ana Oaknin 报告时间：10月19日10:53 - 10:58（柏林当地时间）报告地点：Cologne Auditorium - CityCube A 摘要号：1117P 标题：Durvalumab plus carboplatin/paclitaxel followed by durvalumab for endometrial cancer: tumour mutational burden-high subpopulation efficacy analyses from the DUO-E trial 讲者：Shannon Westin 摘要号：1159P 标题：Validation of transcriptome profiling for prognostication of metastatic endometrial carcinoma beyond p53 molecular subgroup: ancillary results from the UTOLA GINECO trial 讲者：Guillaume Beinse 摘要号：1160P 标题：Immune landscape heterogeneity in endometrial carcinoma – ancillary analyses of GINECO UTOLA trial and CARPEM cohort 讲者：Julie Berthet 摘要号：1161P 标题：Transcriptomic and genomic profiles of chromosomally unstable endometrial tumors: Ancillary analyses of the GINECO UTOLA trial and CARPEM cohort 讲者：Juliette Renard 摘要号：957P 标题：Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) Part 1 final analysis 讲者：Vicky Makker 注：*截止到2025年10月撰写：医脉通编辑部审校：医脉通编辑部排版：Atai 执行：Zelda 本平台旨在为医疗卫生专业人士传递更多医学信息。本平台发布的内容，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。如该等信息被用于了解医学信息以外的目的，本平台不承担相关责任。本平台对发布的内容，并不代表同意其描述和观点。若涉及版权问题，烦请权利人与我们联系，我们将尽快处理。

临床3期临床结果临床终止

2025-10-14

·阿斯利康中国

阿斯利康携四项重磅研究首发数据亮相欧洲肿瘤内科学会（ESMO）年会，进一步彰显重新定义癌症治疗的雄心

● DESTINY-Breast11与DESTINY-Breast05两项研究入选主席研讨会（Presidential Symposium），凸显德曲妥珠单抗在治疗HER2阳性早期乳腺癌中的潜在价值 ● TROPION-Breast02研究数据将展示德达博妥单抗在转移性三阴性乳腺癌这一最具侵袭性的乳腺癌分型中的治疗潜力 ● POTOMAC研究的无病生存期数据与MATTERHORN研究的生存期数据将展示度伐利尤单抗在早期膀胱癌与胃癌治疗中的获益重磅发布 2025年10月14日，上海——阿斯利康将于2025年10月17日至21日召开的欧洲肿瘤内科学会（ESMO）年会上，凭借行业领先的多样化产品与管线布局的全新研究数据，进一步彰显其重新定义癌症治疗格局的雄心壮志。本次大会上，阿斯利康将公布逾95项摘要，涵盖9款已获得批准药物及9款潜在新药，包括2项入选重磅主席研讨会（Presidential Symposium）的摘要以及26项口头报告。其中主要亮点包括： DESTINY-Breast11：评估德曲妥珠单抗序贯THP方案（紫杉醇、曲妥珠单抗及帕妥珠单抗）用于高风险HER2阳性早期乳腺癌新辅助治疗的III期临床研究（主席研讨会1，摘要#291O）。 DESTINY-Breast05：评估德曲妥珠单抗用于HER2阳性早期乳腺癌（新辅助治疗后存在残留浸润病灶并具有高复发风险）的III期临床研究（主席研讨会1，摘要#LBA1）。 TROPION-Breast02：评估德达博妥单抗用于一线治疗无法接受免疫治疗的局部复发性不可手术或转移性三阴性乳腺癌（TNBC）患者的III期临床研究（优选论文摘要#LBA21）。 POTOMAC：评估度伐利尤单抗联合卡介苗（BCG）诱导与维持治疗，用于高危非肌层浸润性膀胱癌（NMIBC）患者的III期临床研究（优选论文摘要#LBA108）。 MATTERHORN：公布III期临床研究的最终总生存期（OS）结果，评估度伐利尤单抗联合FLOT化疗作为可切除的早期和局部晚期的胃和胃⻝管结合部腺癌（GEJ）患者围手术期治疗中的临床获益（优选论文摘要#LBA81）。高书璨(Susan Galbraith) 阿斯利康全球执行副总裁全球肿瘤研发负责人我们正加速推进多元创新疗法管线，以变革乳腺癌患者的治疗格局。在本届ESMO大会上，我们将公布TROPION-Breast02、DESTINY-Breast11和DESTINY-Breast05研究的数据和重要进展。同时，我们也将展示新一代潜在抗肿瘤新药的数据，包括saruparib联合新型激素疗法用于前列腺癌领域，靶向叶酸受体的抗体偶联药物torvu-sam用于卵巢癌领域，以及rilvegostomig用于在非小细胞肺癌领域。 Dave Fredrickson 阿斯利康全球执行副总裁肿瘤业务负责人我们业界领先的肿瘤产品组合在本次ESMO持续展现强劲势头，首次公布了四项关键研究的数据。其中，不仅有德曲妥珠单抗和德达博妥单抗在乳腺癌领域的重大进展，度伐利尤单抗的POTOMAC试验结果也证明了免疫疗法为早期膀胱癌治疗带来的益处，进而阐释我们的策略——将前沿治疗引入癌症早期这一患者最能够获益的阶段。其它亮点包括： FONTANA：评估靶向叶酸受体α（FRα）的抗体药物偶联物AZD5335用于铂耐药复发性卵巢癌患者的I/IIa期首次人体临床试验（简短口头报告摘要#1065MO）。 PETRANHA：评估saruparib联合雄激素受体通路抑制剂用于治疗转移性前列腺癌患者的I/II期临床研究（简短口头报告摘要#2384MO）。 ARTEMIDE-01：评估rilvegostomig用于检查点抑制剂初治的转移性非小细胞肺癌（NSCLC）患者的I/II期临床研究（简短口头报告摘要#1853MO）。 FLAURA2：在奥希替尼合化疗治疗晚期EGFR突变NSCLC患者的FLAURA2 III期临床研究中存在不良预后因素患者的探索性OS分析（优选论文摘要#LBA77）。 CAPItello-281：卡匹色替联合阿比特龙和雄激素剥夺疗法（ADT）用于PTEN缺陷的新发转移性激素敏感性前列腺癌（mHSPC）的III期临床研究（优选论文摘要#2383O）。 TROPION-PanTumor03：评估德达博妥单抗联合rilvegostomig治疗局晚期或转移性尿路上皮癌（a/mUC）患者的疗效： II期TROPION-PanTumor03研究结果结果（简短口头报告摘要 #3072MO）。 BEGONIA：德达博妥单抗联合度伐利尤单抗用于既往未经治疗的不可切除、局部晚期或转移性三阴性乳腺癌（TNBC）患者的BEGONIA Ib/II期试验最终结果（口头报告摘要#555MO）。阿斯利康与第⼀三共联合开发和商业化德曲妥珠单抗与德达博妥单抗；与默沙东（默沙东是美国新泽⻄州罗威市默克公司的公司商号）联合开发和商业化奥拉帕利；与和黄医药合作开发和商业化赛沃替尼。Rilvegostomig是一种靶向PD-1和TIGIT的双特异性抗体，其中TIGIT部分源自Compugen公司临床阶段的抗TIGIT抗体COM902。阿斯利康在2025年 ESMO年会期间的重要演讲1 主要作者摘要标题报告详情(CEST) 抗体偶联药物 Harbeck, N DESTINY-Breast11: neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC). Abstract #291O Presidential 1 18 October 2025 4:30 PM Geyer, C Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with high-risk human epidermal growth factor receptor 2–positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy (tx): Interim analysis of DESTINY-Breast05. Abstract #LBA1 Presidential 1 18 October 2025 4:52 PM Dent, R. First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase 3 TROPION-Breast02 trial. Abstract #LBA21 Proffered Paper Session 19 October 2025 9:25 AM Loibl, S Trastuzumab deruxtecan (T-DXd) + pertuzumab vs taxane + trastuzumab + pertuzumab (THP) for patients with HER2+ advanced/metastatic breast cancer: additional analysis of DESTINY-Breast09 in key subgroups of interest. Abstract #LBA18 Proffered Paper Session 19 October 2025 8:30 AM Rha, SY Datopotamab deruxtecan (Dato-DXd) + rilvegostomig (rilve) in patients (pts) with locally advanced or metastatic urothelial cancer (a/mUC): Results from the phase 2 TROPION-PanTumor03 study. Abstract #3072MO Mini Oral Session 17 October 2025 4:10 PM Oaknin, A First-in-human study of AZD5335, a folate receptor α (FRα)-targeted antibody-drug conjugate, in patients with platinum-resistant recurrent ovarian cancer. Abstract #1065MO Mini Oral Session 19 October 2025 10:53 AM Schmid, P Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment (tx) for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Final results from the phase 1b/2 BEGONIA study. Abstract #555MO Mini Oral Session 20 October 2025 10:50 AM Raghav, K Trastuzumab deruxtecan (T DXd) in patients (pts) with HER2-positive (HER2+) metastatic colorectal cancer (mCRC): Final analysis of DESTINY-CRC02, a randomized, phase 2 trial. Abstract #737P Poster Session Peng, Z Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA) who received prior anti-HER2 treatment (Tx) other than / in addition to trastuzumab in DESTINY-Gastric06 (DG-06) Abstract #2105P Poster Session Shen, L Risk of hepatitis B virus reactivation (HBVr) in patients (pts) with past or resolved HBV or inactive chronic HBV infection treated with trastuzumab deruxtecan (T-DXd) in the DESTINY-Gastric06 (DG-06) trial. Abstract #2175P Poster Session Pietrantonio, F Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) plus paclitaxel (PTX) in second-line (2L) treatment of patients (pts) with HER2+ unresectable/metastatic gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): Additional data from DESTINY-Gastric04 (DG-04). Abstract #2099P Poster Session Makker, V Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) Part 1 final analysis. Abstract #957P Poster Session Lee, J-Y Trastuzumab deruxtecan (T-DXd) in pretreated patients (pts) with HER2-expressing solid tumors: exploratory biomarker analysis of DESTINY-PanTumor02 (DP-02) Part 1. Abstract #145P Poster Session 免疫肿瘤学 Tabernero, J MATTERHORN Phase III trial of Imfinzi (durvalumab) perioperative Imfinzi (durvalumab) plus FLOT chemotherapy in patients with resectable, early-stage and locally advanced gastric and gastroesophageal junction (GEJ) cancers. Abstract #LBA81 Proffered Paper Session 17 October 2025 2:00 PM De Santis, M Durvalumab (D) in Combination with Bacillus Calmette-Guérin (BCG) for BCG-naïve, High-risk Non-muscle-invasive Bladder Cancer (NMIBC): Results from the Phase 3, Open-label, Randomised POTOMAC Trial. Abstract #LBA108 Proffered Paper Session 17 October 2025 2:10 PM Larkin, J First results from RAMPART: An international phase 3 randomised-controlled trial of adjuvant durvalumab monotherapy or combined with tremelimumab for resected primary renal cell carcinoma (RCC) led by MRC CTU at UCL. Abstract #LBA93 Proffered Paper Session 18 October 2025 9:20 AM Aghajanian, C Durvalumab + paclitaxel/carboplatin + bevacizumab followed by durvalumab, bevacizumab + olaparib maintenance in patients with newly diagnosed non-tBRCA-mutated advanced ovarian cancer: final overall survival from DUO-O/ENGOT-ov46/GOG-3025. Abstract #LBA44 Mini Oral Session 19 October 2025 11:31 AM Goss, G CCTG BR.31: Adjuvant durvalumab (D) in resected non-small-cell lung cancer (NSCLC): final overall survival (OS) and minimal residual disease (MRD) analyses. Abstract #LBA68 Mini Oral Session 20 October 2025 3:20 PM Heymach, J Association of radiomic features ± on-treatment ctDNA detection with treatment outcomes in patients with resectable NSCLC: exploratory analyses from AEGEAN。 Abstract #LBA70 Mini Oral Session 20 October 2025 3:50 PM Wermke, M Tarlatamab with first-line chemoimmunotherapy for extensive stage small cell lung cancer (ES-SCLC): DeLLphi-303 study. Abstract #2757O Proffered Paper Session 18 October 2025 8:30 AM Loibl, S Durvalumab in Combination with Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC) – Long-term Analysis from the GeparNuevo Trial. Abstract #292MO Mini Oral Session 19 October 2025 10:15 AM Van der Heijden, M Health-related quality of life (HRQoL) from the NIAGARA trial of perioperative durvalumab (D) plus neoadjuvant chemotherapy (NAC) in muscle-invasive bladder cancer (MIBC). Abstract #3069MO Mini Oral Session 17 October 2025 4:00 PM Sangro, B Pooled efficacy and safety outcomes with tremelimumab plus durvalumab in participants (pts) with unresectable hepatocellular carcinoma (uHCC) from the combined China extension and global cohorts in the Phase 3 HIMALAYA study. Abstract #1494P Poster Session Westin, S Durvalumab plus carboplatin/paclitaxel followed by durvalumab for endometrial cancer: Tumour mutational burden-high subpopulation efficacy analyses from the DUO-E trial. Abstract #1117P Poster Session Leal, TA Global quantitative assessment of multidisciplinary team (MDT) care in early-stage NSCLC. Abstract #1794P Poster Session Reck, M Neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery (Sx) and adjuvant D or CRT and consolidation D in patients (pts) with resectable or borderline resectable stage IIB–IIIB NSCLC: interim analysis (IA) of the phase 2 MDT-BRIDGE study. Abstract #LBA65 Proffered Paper Session 18 October 2025 9:15 AM Maruki, Y CELEBRATE Study (JCOG2107E): A Multicenter, Open-label, Phase III Trial of Etoposide, Carboplatin, and Durvalumab in First-line Treatment of Unresectable or Recurrent Digestive NEC. Abstract #1734TiP Poster Session Oudard, S A phase IIIb, open-label, single-arm, global study of perioperative durvalumab (D) with neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) or gemcitabine/cisplatin (gem/cis) in patients with muscle-invasive bladder cancer (MIBC) (NIAGARA-2). Abstract #3133eTiP ePoster Session 双特异性抗体 Chul Cho, B Efficacy and Safety of Rilvegostomig, an Anti-PD-1/TIGIT Bispecific Antibody, for Checkpoint Inhibitor (CPI)-Naïve Metastatic Non-Small-Cell Lung Cancer (mNSCLC): ARTEMIDE-01. Abstract #1853MO Mini Oral Session 20 October 2025 10:25 AM Slomovitz, BM A randomized Phase 3 study of first-line (1L) trastuzumab deruxtecan (T-DXd) with rilvegostomig or pembrolizumab in patients with HER2-expressing, mismatch repair-proficient (pMMR), primary advanced or recurrent endometrial cancer (EC): DESTINY-Endometrial01/GOG-3098/ENGOT-EN24. Abstract #1223TiP Poster Session Naidoo, J ARTEMIDE-Lung04: A Phase 3, randomised, double-blind, global study of rilvegostomig or pembrolizumab monotherapy as first-line (1L) treatment for patients with metastatic non-small cell lung cancer (mNSCLC) and programmed cell death ligand-1 (PD-L1) expression ≥50%. Abstract #2025TiP Poster Session 肿瘤驱动因子和耐药性 Jänne, PA FLAURA2: exploratory overall survival (OS) analysis in patients (pts) with poor prognostic factors treated with osimertinib (osi) ± platinum-pemetrexed chemotherapy (CTx) as first-line (1L) treatment for EGFR-mutated (EGFRm) advanced NSCLC. Abstract #LBA77 Proffered Paper Session 17 October 2025 4:56 PM Mayer, E Patient-reported outcomes (PROs) from the SERENA-6 trial of camizestrant (CAMI) + CDK4/6 inhibitor (CDK4/6i) for emergent ESR1m during first-line (1L) endocrine-based therapy and ahead of disease progression in patients (pts) with HR+/HER2- advanced breast cancer (ABC). Abstract #486MO Mini Oral Session 20 October 2025 10:25 AM Arriola, E Molecular residual disease (MRD) analysis from the LAURA study of osimertinib (osi) in unresectable (UR) stage III EGFR-mutated (EGFRm) NSCLC. Abstract #1817MO Mini Oral Session 20 October 2025 2:55 PM Park, YH Visual symptom questionnaire results from SERENA-6, a Phase 3 study of switch to camizestrant (CAMI) + CDK4/6 inhibitor (CDK4/6i) at emergence of ESR1m during first-line (1L) therapy for patients (pts) with HR+/HER2- advanced breast cancer (ABC). Abstract #528P Poster Session Chu, Q SAVANNAH: Safety and tolerability of osimertinib (osi) + savolitinib (savo) in EGFRm advanced NSCLC with MET overexpression and/or amplification (OverExp/Amp) following disease progression on osi. Abstract #1955P Poster Session Rotow, J MET testing and treatment (tx) sequencing after progression on first line (1L) osimertinib (osi) in patients (pts) with EGFRm advanced NSCLC and acquired MET overexpression and/or amplification (OverExp/Amp): Interim analysis of a global real world (rw) study. Abstract #1967P Poster Session Yu, Y ctDNA analysis in phase 3 SACHI trial: Savolitinib (savo) plus osimertinib (osi) versus chemotherapy (chemo) in MET-amplified (METamp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI). Abstract #1954P Poster Session DNA损伤应答 Azad, AA First interim efficacy analysis of the Phase 1/2 PETRANHA trial of saruparib + androgen receptor pathway inhibitors (ARPI) in patients (pts) with metastatic prostate cancer (mPC). Abstract #2384MO Mini Oral Session 17 October 2025 2:35 PM Fizazi, K A Phase 3 study of capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC): CAPItello-281. Abstract #2383O Proffered Paper Session 19 October 2025 11:19 AM Rugo, HS Capivasertib with fulvestrant as first- and second-line endocrine therapy in PIK3CA/AKT1/PTEN-altered hormone receptor-positive advanced breast cancer: Subgroup analysis from the Phase 3 CAPItello-291 trial. Abstract #526P Poster Session Gao, Q Final overall survival (OS) analysis of L-MOCA: olaparib maintenance monotherapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC). Abstract #1090P Poster Session AI驱动的临床试验 Gonuguntla, HK Real-World Validation of AI-defined Lung Nodule Malignancy Score (qXR-LNMS) in Predicting Risk of Lung Cancer: Interim results from Phase 2. Abstract #2978P Poster Session 1阿斯利康在2025年ESMO年会将公布逾90个摘要，涵盖其产品和管线中的分子药物。关于阿斯利康肿瘤领域的研究阿斯利康正引领着肿瘤领域的⼀场⾰命，致⼒提供多元化的肿瘤治疗⽅案，以科学探索肿瘤领域的复杂性，发现、研发并向患者提供改变⽣命的药物。阿斯利康专注于最具挑战性的肿瘤疾病，通过持续不断的创新，阿斯利康已经建⽴了⾏业领先的多元化的产品组合和管线，持续推动医疗实践变⾰，改变患者体验。阿斯利康以期重新定义癌症治疗并在未来攻克癌症。关于阿斯利康阿斯利康（LSE/STO/Nasdaq: AZN）是⼀家科学⾄上的全球⽣物制药企业，专注于研发、⽣产及营销处⽅类药品，重点关注肿瘤、罕⻅病以及包括⼼⾎管肾脏及代谢、呼吸及免疫在内的⽣物制药等领域。阿斯利康全球总部位于英国剑桥，业务遍布超过125个国家，创新药物惠及全球数百万患者。更多信息，请访问www.astrazeneca.com。关于阿斯利康中国阿斯利康⾃1993年进⼊中国以来，专注中国患者需求最迫切的治疗领域，包括肿瘤、⼼⾎管、肾脏、代谢、呼吸、消化、罕⻅病、疫苗抗体及⾃体免疫等，已将40多款创新药物带到中国。阿斯利康中国总部位于上海，并在上海和北京设⽴全球战略研发中⼼，在北京、⼴州、杭州、成都、⻘岛设⽴区域总部，在⽆锡、泰州、⻘岛建⽴全球⽣产供应基地，向全球70多个市场输送优质创新药品。声明：本文研究中涉及的多种药品用法尚未在中国获批适应症，阿斯利康不推荐任何未被批准的药品使用。内容来源：新闻稿（内部审批号：CN-169484）

临床3期临床成功免疫疗法临床结果

100 项与卡匹色替相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11371	-	-	DB12218

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
ER阳性/HER2阴性乳腺癌	欧盟	AstraZeneca AB	2024-06-17
ER阳性/HER2阴性乳腺癌	冰岛	AstraZeneca AB	2024-06-17
ER阳性/HER2阴性乳腺癌	列支敦士登	AstraZeneca AB	2024-06-17
ER阳性/HER2阴性乳腺癌	挪威	AstraZeneca AB	2024-06-17
乳腺癌	加拿大	AstraZeneca Canada, Inc.	2024-01-26
HR阳性/HER2阴性乳腺癌	美国	AstraZeneca Pharmaceuticals LP	2023-11-16

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
局部晚期乳腺癌	临床3期	西班牙	AstraZeneca PLC	2025-01-07
晚期乳腺癌	临床3期	中国	AstraZeneca AB	2024-09-26
转移性去势抵抗性前列腺癌	临床3期	美国	AstraZeneca PLC	2022-03-25
转移性去势抵抗性前列腺癌	临床3期	中国	AstraZeneca PLC	2022-03-25
转移性去势抵抗性前列腺癌	临床3期	日本	AstraZeneca PLC	2022-03-25
转移性去势抵抗性前列腺癌	临床3期	澳大利亚	AstraZeneca PLC	2022-03-25
转移性去势抵抗性前列腺癌	临床3期	比利时	AstraZeneca PLC	2022-03-25
转移性去势抵抗性前列腺癌	临床3期	巴西	AstraZeneca PLC	2022-03-25
转移性去势抵抗性前列腺癌	临床3期	加拿大	AstraZeneca PLC	2022-03-25
转移性去势抵抗性前列腺癌	临床3期	智利	AstraZeneca PLC	2022-03-25

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


CAPItello-291 (ASCO2025)	N/A	HR阳性/HER2阴性乳腺癌 PIK3CA \| AKT \| PTEN ... 更多	34	Capivasertib	觸繭糧糧鹹積蓋餘齋製(繭繭窪憲遞觸鑰網壓選) = 遞糧鏇蓋鏇鏇鑰積糧鹹範範遞糧鑰築網蓋衊餘 (醖夢鹽醖鬱鏇艱鹹簾膚, 2.4 ~ 7.6) 更多	积极	2025-05-30
				Alpelisib	-
NCT04862663 (CAPItello-292, ESMO_BC2025)	临床1期	HR阳性HER2阴性淋巴结阳性乳腺癌	41	Capivasertib 320mg BID + Ribociclib 400mg QD + Fulvestrant 500mg	淵糧衊繭獵衊鹽壓憲構(糧艱衊鏇觸蓋網鬱鬱積) = 憲繭獵網繭膚簾選鏇艱廠餘獵鹹鬱範壓鬱鹽糧 (窪衊觸蓋獵觸壓鹹艱鑰 ) 更多	积极	2025-05-14
				Capivasertib 400mg BID + Ribociclib 400mg QD + Fulvestrant 500mg	淵糧衊繭獵衊鹽壓憲構(糧艱衊鏇觸蓋網鬱鬱積) = 夢選艱襯蓋願網夢夢鹹廠餘獵鹹鬱範壓鬱鹽糧 (窪衊觸蓋獵觸壓鹹艱鑰 ) 更多
NCT05348577 (CAPItello-280, NEWS) 人工标引	临床3期	转移性去势抵抗性前列腺癌	-	Truqap + docetaxel + androgen-deprivation therapy	築鹹網繭蓋願獵夢繭餘(簾鏇夢繭鹽鑰襯齋築顧) = unlikely meet the dual primary endpoints 構衊艱蓋鏇衊鹹顧構襯 (廠淵壓艱淵製憲鹹膚鹽 ) 未达到更多	不佳	2025-04-30
				placebo + docetaxel + androgen-deprivation therapy
AACR2025	临床3期	前列腺癌 PTEN-deficient	-	Docetaxel	範願顧齋選遞襯艱醖艱(鑰觸積構齋膚觸網觸觸) = 願糧鏇鬱觸製廠構蓋獵願蓋膚襯積襯齋鹹構餘 (繭構鹽構艱膚餘鑰積壓 ) 更多	-	2025-04-28
				Docetaxel + Capivasertib	膚築願鏇窪顧鏇鹽廠積(構獵壓構積獵膚獵壓選) = 築衊製鹽顧顧範選憲齋築糧繭廠窪齋餘夢鬱鏇 (膚繭願夢壓鹽繭範餘鏇 ) 更多
NCT04439123 (NCI-MATCH, Pubmed \| JCO Precis Oncol)	临床2期	难治恶性实体肿瘤 \| 晚期恶性实体瘤 \| 晚期淋巴瘤 ... AKT1 E17K \| TP53 \| EGFR 更多	25	Capivasertib 480 mg	鹹範齋醖夢壓艱遞鏇襯(觸獵鹹夢餘網餘積製築) = 廠鬱膚窪壓襯艱夢製窪夢網構遞顧鹹膚憲醖齋 (壓選窪選膚廠簾鬱築繭 )	积极	2025-03-01
NCT04305496 (CAPItello-291, Pubmed \| J Clin Oncol)	临床3期	PIK3CA突变/HR阳性/HER2阴性乳腺癌 PIK3CA \| AKT1 \| PTEN	708	Capivasertib 400 mg twice daily with fulvestrant	製觸積壓齋壓顧網構製(製觸淵廠觸繭糧選願鏇): HR = 0.6 (95% CI, 0.51 ~ 0.71) 更多	积极	2024-12-01
				Placebo with fulvestrant
NCT04556773 (DESTINY-Breast08, SABCS2024) 人工标引	临床1期	HER2低表达乳腺癌 HER2-low	60	Trastuzumab deruxtecan (T-DXd) + Capecitabine (CAPE)	壓鬱製觸醖糧憲願簾壓(蓋網淵廠廠鬱鑰鑰選築) = 顧積蓋衊衊膚構築壓網鬱觸範鏇膚壓蓋鑰蓋糧 (鏇範網餘簾鹽積艱網觸 ) 更多	积极	2024-11-26
				Trastuzumab deruxtecan (T-DXd) + Capivasertib (CAPI)	壓鬱製觸醖糧憲願簾壓(蓋網淵廠廠鬱鑰鑰選築) = 鹽範窪憲膚廠艱獵鏇艱鬱觸範鏇膚壓蓋鑰蓋糧 (鏇範網餘簾鹽積艱網觸 ) 更多
NCT04493853 (CAPItello-281, Company_Website) 人工标引	临床3期	激素依赖性前列腺癌 PTEN Deficient Expression	-	capivasertib + abiraterone + androgen deprivation therapy	鬱顧蓋壓蓋窪窪選顧鹹(憲積獵糧簾窪窪選範遞) = statistically significant and clinically meaningful improvement 淵築願廠顧鏇顧繭積淵 (鑰簾選簾製夢鏇壓齋顧 ) 更多	积极	2024-11-25
				placebo + abiraterone + androgen deprivation therapy
NCT04305496 (CAPItello-291, Pubmed \| Future Oncol)	临床3期	HR阳性乳腺癌 PIK3CA \| AKT1 \| PTEN	-	Capivasertib plus Fulvestrant	簾遞構襯壓鑰衊築繭獵(衊鹹繭築積製獵築範鹽) = The most common side effects experienced by participants included diarrhea 製襯遞鏇網觸簾糧蓋鑰 (壓鏇願齋鏇餘鬱顧蓋夢 ) 更多	积极	2024-11-25
				Placebo plus Fulvestrant
NCT04305496 (CAPItello-291, Pubmed) 人工标引	临床3期	HR阳性/HER2阴性乳腺癌 HER2 Negative \| HR Positive	901	capivasertib + fulvestrant	餘築繭築範廠衊窪構膚(簾觸築鹹廠膚鏇網鬱醖) = 繭製壓範築壓積膚壓構鏇築鹹鬱選鏇選壓積獵 (淵鏇廠襯艱顧築衊膚鹽, 9.1 ~ 16.7) 更多	积极	2024-09-01
				placebo + fulvestrant	餘築繭築範廠衊窪構膚(簾觸築鹹廠膚鏇網鬱醖) = 衊廠觸廠衊鏇鬱衊遞顧鏇築鹹鬱選鏇選壓積獵 (淵鏇廠襯艱顧築衊膚鹽, 2.0 ~ 16.4) 更多